Bausch + Lomb’s parent grows by 16%, turns around

Valeant Pharmaceuticals, the company that bought Bausch + Lomb in August 2013, reported net income of $74.5 million for the first quarter ended March 31 against a loss of $20.3 million in the year-ago period. Total sales grew by 16 percent to $2,190 million, led by a 39 percent increase ...

To continue reading this article register now.

Already an Eyewear Intelligence subscriber? Sign in here.


Become a member today for full access from just €6,70 a week!

Buying a membership today will give you:

  • Unlimited access to - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation

Or sign-up for a trial month for just 9,90€. To continue reading this article register now.